Psychopharmacology

“This is the first study to assess the standalone drug effects of MM-120 in the absence of any psychotherapeutic intervention.”

Researchers performed a systematic review and meta-analysis of the effects of clozapine on cognitive function in patients with treatment-resistant schizophrenia.

From adjunctive cariprazine for the treatment of major depressive disorder to a new app for prescribing antidepressants and antipsychotics, here are highlights from the week in Psychiatric Times.

Researchers performed a double-blind, placebo-controlled pilot study of solriamfetol.

The Psymatic Treatment Optimizer facilitates selecting agents ranked by adverse-effect profile with consideration of patient preference and tolerance.

From dopamine detoxification for problem gaming to connections between bacteria and anxiety and depression, here are highlights from the week in Psychiatric Times.

What is new in research on bipolar disorder?

The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of November.

The FDA’s decision is set for September 2024.

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.

"During the past 5 years has gabapentin retained its position as one of the top 10 drugs prescribed in the United States."

These results were instrumental in securing the FDA approval of the drug for the treatment of schizophrenia in adults in April 2023.

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.

Researchers performed a head-to-head trial of vortioxetine versus desvenalfaxine in patients with depression and partial response to SSRIs.

The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.

The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of October.

What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.

From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.

"Cumulatively, the findings of such reports have led to a concerted effort to encourage physicians to monitor patients for manic symptoms on initiation, reintroduction, and dose modulation of corticosteroid therapy."

What is the risk of diabetes, hypertension, or hyperlipidemia with antipsychotic polypharmacy in patients with schizophrenia? Researchers investigated these associations in a population-based prospective cohort study.

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

“Are my other medications making my depression worse?” Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023. As these shortages continue, here's how you can best support your patients with ADHD.